Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Receivables - Net of $394.8 million for Q1 2026, down 40.12% year-over-year from $659.4 million in Q1 2025, and down 0.85% quarter-over-quarter from $398.2 million in Q4 2025.
Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $394.8 million for Q1 2026.
- In Q1 2026, Receivables - Net fell 40.12% year-over-year to $394.8 million; the TTM figure through Mar 2026 stood at $394.8 million (down 40.12% YoY), while the FY2025 annual figure was $398.2 million, down 33.85% from the prior year.
- Receivables - Net for Q1 2026 stood at $394.8 million, down from $398.2 million in the prior quarter.
- The five-year high for Receivables - Net was $659.4 million in Q1 2025, with the low at $178.2 million in Q1 2022.
- The 5-year median for Receivables - Net is $378.8 million (2024), against an average of $360.5 million.
- The sharpest annual moves came in 2023 and 2026: Receivables - Net surged 86.55% in 2023, then slumped 40.12% in 2026.
- Sarepta Therapeutics' Receivables - Net stood at $214.6 million in 2022, then soared by 86.55% to $400.3 million in 2023, then soared by 50.37% to $602.0 million in 2024, then tumbled by 33.85% to $398.2 million in 2025, then declined by 0.85% to $394.8 million in 2026.
- Business Quant data shows SRPT's Receivables - Net at $394.8 million in Q1 2026, $398.2 million in Q4 2025, and $395.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 376.82 Mn |
| Jun 30, 2026 | 376.82 Mn |
| Mar 31, 2026 | 394.82 Mn |
| Mar 31, 2026 | 394.82 Mn |
| Dec 31, 2025 | 398.20 Mn |
| Dec 31, 2025 | 398.20 Mn |
| Sep 30, 2025 | 395.74 Mn |
| Sep 30, 2025 | 395.74 Mn |
| Jun 30, 2025 | 527.30 Mn |
| Jun 30, 2025 | 527.30 Mn |
| Mar 31, 2025 | 659.40 Mn |
| Mar 31, 2025 | 659.40 Mn |
| Dec 31, 2024 | 601.99 Mn |
| Dec 31, 2024 | 601.99 Mn |
| Sep 30, 2024 | 434.52 Mn |
| Sep 30, 2024 | 434.52 Mn |
| Jun 30, 2024 | 360.00 Mn |
| Jun 30, 2024 | 360.00 Mn |
| Mar 31, 2024 | 378.81 Mn |
| Mar 31, 2024 | 378.81 Mn |